5988
C. M. Lombardo et al. / Bioorg. Med. Chem. Lett. 22 (2012) 5984–5988
10.01 (2H, s, 2 ꢁ NH), 9.44 (2H, s, 2 ꢁ C@CH), 8.61 (2H, s, 2 ꢁ ArH), 8.44–8.43
References and notes
(2H, m, 2 ꢁ ArH), 8.17–8.09 (4H, m, 4 ꢁ ArH), 7.82–7.80 (2H, m, 2 ꢁ ArH), 7.68–
7.65 (2H, m, 2 ꢁ ArH), 7.61–7.57 (2H, m, 2 ꢁ ArH), 3.23 (4H, s, 2 ꢁ CH2), 2.64 (8
H, quartet, J = 7.2 Hz, 4 ꢁ CH2), 1.05 (12 H, t, J = 7.2 Hz, 4 x CH3); dC (d6-DMSO,
100 MHz) 170.39 (2 ꢁ C@O), 147.13 (2 x C@CH), 139.76 (2 ꢁ Ar-C), 136.84
(2 ꢁ Ar-C), 133.25 (Ar-C), 132.36 (Ar-C), 130.22 (2 ꢁ Ar-CH), 128.61 (2 ꢁ Ar-C),
128.36 (2 ꢁ Ar-CH), 123.97 (2 ꢁ Ar-CH), 123.89 (2 ꢁ Ar-CH), 120.15
(2 ꢁ C@CH), 119.30 (2 ꢁ Ar-CH), 114.74 (2 ꢁ Ar-CH), 110.88 (2 ꢁ Ar-CH),
57.25 (2 ꢁ CH2), 47.81 (4 ꢁ CH2), 11.83 (4 ꢁ CH3); HRMS m/z calc.
1. Burge, S.; Parkinson, G. N.; Hazel, P.; Todd, A. K.; Neidle, S. Nucleic Acids Res.
2006, 34, 5402.
2. Phan, A. T.; Kuryavyi, V.; Luu, K. N.; Patel, D. J. Nucleic Acids Res. 2007, 35, 6517.
3. Huppert, J. L.; Balasubramanian, S. Nucleic Acids Res. 2007, 35, 406.
4. Balasubramanian, S.; Hurley, L. H.; Neidle, S. Nat. Rev. Drug Discovery 2011, 10,
261.
5. Neidle, S. Curr. Opin. Struct. Biol. 2009, 19, 1.
6. Adrian, M.; Heddi, B.; Phan, A. T. Methods 2012, doi.org/10.1016/
j.ymeth.2012.05.003.
7. Monchaud, D.; Teulade-Fichou, M.-P. Org. Biomol. Chem. 2008, 6, 627.
8. Neidle, S. Therapeutic Aspects of Quadruplex Nucleic Acids; Academic Press: San
Diego, 2011.
9. Yang, D. Z.; Okamoto, K. Future Med. Chem. 2010, 2, 619.
10. See for example: (a) Sparapani, S.; Haider, S. M.; Doria, F.; Gunaratnam, M.;
Neidle, S. J. Amer. Chem. Soc. 2010, 132, 12263; (b) Tran, P. L.; Largy, E.; Hamon,
F.; Teulade-Fichou, M. P.; Mergny, J.-L. Biochimie 2011, 93, 1288; (c) Dash, J.;
Das, R. N.; Hegde, N.; Pantosß, G. D.; Shirude, P. S.; Balasubramanian, S.
Chemistry 2012, 18, 554.
11. (a) Siddiqui-Jain, A.; Grand, C. L.; Bearss, D. J.; Hurley, L. H. Proc. Natl. Acad. Sci.
U.S.A. 2002, 99, 11593; (b) Brown, R. V.; Danford, F. L.; Gokhale, V.; Hurley, L.
H.; Brooks, T. A. J. Biol. Chem. 2011, 286, 41018.
12. (a) Gunaratnam, M.; Swank, S.; Haider, S. M.; Galesa, K.; Reszka, A. P.; Beltran,
M.; Cuenca, F.; Fletcher, J. A.; Neidle, S. J. Med. Chem. 2009, 52, 3774; (b)
McLuckie, K. I.; Waller, Z. A.; Sanders, D. A.; Alves, D.; Rodriguez, R.; Dash, J.;
McKenzie, G. J.; Venkitaraman, A. R.; Balasubramanian, S. J. Amer. Chem. Soc.
2011, 133, 2658.
13. Rodriguez, R.; Miller, K. M.; Forment, J. V.; Bradshaw, C. R.; Nikan, M.; Britton,
S.; Oelschlaegel, T.; Xhemalce, B.; Balasubramanian, S.; Jackson, S. P. Nat. Chem.
Biol. 2012, 8, 301.
14. (a) Wieland, M.; Hartig, J. S. Chem. Biol. 2007, 14, 757; (b) Bugaut, A.;
15. Greer, S. N.; Metcalf, J. L.; Wang, Y.; Ohh, M. EMBO J. 2012, 31, 2448.
16. Jonasch, E.; Futreal, A.; Davis, I.; Bailey, S.; Kim, W. Y.; Brugarolas, J.; Giaccia, A.
J.; Kurban, G.; Pause, A.; Frydman, J.; Zurita, A.; Rini, B. I.; Sharma, P.; Atkins,
17. Keith, B.; Johnson, R. S.; Simon, M. C. Nat. Rev. Cancer 2011, 12, 9.
18. Yang, Q. C.; Zeng, B. F.; Dong, Y.; Shi, Z. M.; Jiang, Z. M.; Huang, J. Jpn J Clin Oncol.
2007, 37, 127.
19. Mizobuchi, H.; García-Castellano, J. M.; Philip, S.; Healey, J. H.; Gorlick, R. Clin.
Orthop. Relat. Res. 2008, 466, 2052.
20. Chen, C.; Zhou, H.; Wei, F.; Jiang, L.; Liu, X.; Liu, Z.; Ma, Q. J. Orthop. Res. 2011,
29, 143.
21. De Armond, R.; Wood, S.; Sun, D.; Hurley, L. H.; Ebbinghaus, S. W. Biochemistry
2005, 44, 16341.
22. Moorhouse, A. D.; Santos, A. M.; Gunaratnam, M.; Moore, M.; Neidle, S.; Moses,
J. E. J. Amer. Chem. Soc. 2006, 128, 15972.
C
38H43N10O2 [M+H]+ 671.3571, found [M+H]+ 671.3594.
25. Experiments were performed on a BIACORE T200 instrument at 25 °C with
buffer containing 10 mM HEPES, 100 mM KCl, 3 mM EDTA and 0.05% P20
surfactant with the final pH adjusted to 7.3. The steady-state response
obtained (RUobs) was plotted versus the unbound ligand concentration
(Cfree) in the flow solution and fitted to either a single-site or a two-site
model: RUobs= RUmax/site ꢁ (K1Cfree + 2K1K2Cfree2)/(1 + K1Cfree + K1K2Cfree2);
K2= 0 for a single site.
26. Cells and reagents: A498 human renal carcinoma, 786–0 human renal
carcinoma, MCF-7 human breast carcinoma, Mia-Pa-Ca human pancreatic
carcinoma, Panc-1 human pancreatic carcinoma, and PC-3 human prostate
carcinoma cells were obtained from American Type Culture Collection
(Rockville, MD). Human RCC4 and RCC4/VHL cells were obtained from
Professor P. Maxwell (University College London, UK) (Maxwell, P. H.;
Wiesener, M. S.; Chang, G. W.; Clifford, S. C.; Vaux, E. C.; Cockman, M. E.;
Wykoff, C. C.; Pugh, C. W.; Maher, E. R.; Ratcliffe, P. J. Nature, 1999, 399, 271).
RCC4 cells lack pVHL therefore express constitutively high levels of HIF-1
a.
These cells were stably transfected with a wild-type pVHL gene, as previously
described (Cockman, M. E. et al., J. Biol. Chem. 2000, 275, 25733). All cells were
grown in humidified 95% air, 5% CO2 at 37°C in Dulbecco’s modified Eagle’s
medium (DMEM), RPMI or MEM medium supplemented with 10% fetal bovine
serum (FBS) and 2mM L-Glutamine according to advice from ATCC (all
reagents were obtained from Gibco, Invitrogen, UK). HIF-1
a and HIF-2a
antibodies were obtained from BD Transduction Labs, AKT antibody was
obtained from Cell Signalling Biotechnology, and lamin A/C, actin, HIF-1b, HSP-
90, and Raf-1 antibodies were from Santa Cruz Biotechnology.
27. Short-term antiproliferative activity was evaluated by means of the
sulforhodamine
B assay, and calculated as IC50 values for 96 h exposure
Vichai, V.; Kirtikara, K. Nature Protocol. 2006, 1, 1112.
28. Osteosarcoma (HOS, MNNG, MG63, U2OS, SaOS2, OST) and Ewing’s-(TC32,
TC71, TC135) sarcoma cell lines were treated with compound CL67 (with 1 ꢁ, 5
ꢁ or 10 ꢁ IC50) for various times in humidified air, 5% CO2 (normoxia) or 1% O2,
5% CO2, 94% N2 (hypoxia) using an In Vivo Hypoxia Workstation 400. Cell
growth inhibition was measured using the sulphorhodamine B assay, HIF-1
a
protein using Western blotting, HIF-1 transactivation using transient
transfection of cells with a plasmid expressing luciferase under the control of
multiple copies of the hypoxia-response element, and HIF-1a mRNA using RT-
PCR, as previously described Koh, M. Y.; Spivak-Kroizman, T.; Venturini, S.;
Welsh, S.; Williams, R. R.; Kirkpatrick, D. L.; Powis, G. Mol. Cancer Ther. 2008, 7,
90.
29. Wendt, B.; Mulbaier, M.; Wawro, S.; Schultes, C.; Alonso, J.; Janssen, B.; Lewis, J.
J. Med. Chem. 2011, 54, 8471.
30. An, H.; Kim, N. J.; Jung, J. W.; Jang, H.; Park, J. W.; Suh, Y. G. Bioorg. Med. Chem.
Lett. 2011, 21, 6297.
23. Lombardo, C. M.; Sánchez Martínez, I.; Haider, S.; Gabelica, V.; De Pauw, E.;
Moses, J. E.; Neidle, S. Chem. Commun. 2010, 46, 9116.
24. Synthesis and analysis of compound 13 (CL67). 2,7-Diethynylnaphthalene
(20 mg, 0.11 mmol) was dissolved in H2O (1.5 ml) and tBuOH (1.5 ml), then the
azide (84 mg, 0.34 mmol), CuSO4 (2 mg, 0.005 mmol), sodium ascorbate
(11 mg, 0.05 mmol) and bathophenanthrolinedispufonic acid disodium salt
hydrate (clicl catalyst) (6 mg, 0.01 mmol) were added, to give compound CL67
as a brown solid crude (126 mg, quantitative). Prep HPLC gave a beige solid;
HPLC Rt 12.06 minutes, purity 97%; mp 97–99 °C; dH (d6-DMSO, 400 MHz)
31. Mooring, S. R.; Jin, H.; Devi, N. S.; Jabbar, A. A.; Kaluz, S.; Liu, Y.; Van Meir, E. G.;
Wang, B. J. Med. Chem. 2011, 54, 8471.
32. Xia, Y.; Choi, H. K.; Lee, K. Eur. J. Med. Chem. 2012, 49, 24.
33. Welsh, S.; Williams, R.; Kirkpatrick, L.; Paine-Murrieta, G.; Powis, G. Mol. Cancer
Ther. 2004, 3, 233.